Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape

Abstract

Abstract Immunotherapy with checkpoint inhibitors (ICIs) has radically changed the landscape of therapeutic opportunities in oncology, but much still needs to be understood from a mechanistic point of view. There is space for further improving tumors’ response to ICIs, as supported by a strong biological rationale. For this achievement a detailed analysis of tumor cell phenotype with functional dissection of the molecular interactions occurring in the TME is required. Galectin-3 is a pleiotropic tumor relevant molecule, which deserves particular attention in immuno-oncology. Due to its ability to finely modulate immune response in vivo, Galectin-3 is a potential target molecule to be considered for overcoming tumor immune escape.

Keywords

• Immunotherapy, Checkpoint inhibitors
• Galectin-3
• Tumor microenvironment
• Predictive markers of immune-response